Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s

In the business news section of this week’s episode, Axiom Biosciences recently announced its plans to go public and made headlines for its plans to do so on the Hong Kong Exchange rather than a U.S. market. We dig into the company’s reasoning. Then we turn our attention to Latigo’s report of positive Phase IIb data for its non-opioid acute pain candidate, and its plans to go through a planned IPO soon. Switching to some science news, we discuss findings from a study that identified genetic risk factors for fibromyalgia syndrome as well as links to other neurodegenerative, autoimmune, and metabolic diseases. And lastly, a potential base editing therapy for Huntington’s disease that has shown promise in mice.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: StockWatch: Axiom CEO Explains Plans for Hong Kong IPO By Alex Philippidis, GEN Edge, July 27, 2026Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate By Alex Philippidis, GEN Edge, July 30, 2026Genetic Study of Fibromyalgia Points to Neurological Basis GEN, July 29, 2026Base Editing Strategy Alleviates Huntington’s Disease in Mice GEN, July 29, 2026Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD The State of Biologics Testing 2026Charles River Laboratories and GEN, June 10, 2026 Hosted on Acast. See acast.com/privacy for more information.